and now yahoo won't let me post this phase 1 data from Isonep. I'm sure you saw it where all occult type patients had a huge decrease in in choroidal neovascularization (CNV).
Way more evidence for success here but Shark juice rules the day
OHRP has a eye drop which when used religously may do as well as fostiva in people who are already getting shots of Lucentis or whatever. If fostiva becomes able to be mixed with Lucentis(and why isn't it?) what is the point of the shark juice, unless it provides addition benefit on top of the fostiva?
If Isonep by itself or mixed with Lucentis is just as good as Fostiva plus Lucentis , then Fostiva and shark juice are diminished presumably. Huge news.
If Asonep's biomarker is found and PFS doubles that would be huge news.
If Lpathomab monkey data leads to human TBI trials that will be huge news.
Hopefully he's talking with Pfizer and others about finding the biomarker for Asonep.
Amoung other things.
I do not own this stock, I am assuming anyone who thinks it's a good investment might have something to say about the products. If that's clueless, then I guess I am. I am not a rude arshole though, apparently you are.
if they want Pfizer to make an offer I suppose they would give them some more info if they have it, but they probably would give it to us, and everyone else also. They want the best partner (or highest bidder) and that may not be Pfizer.
That is, if Pfizer does not make an accepted offer on Asonep in the 75 days then Lpath is free to go make one with anybody else.
The timing has nothing to do with the ROFR.
Pfizer has to decide to opt in on Asonep within 75 days of getting the Isonep results.
I wonder if some people are thinking they upped the dose because it wasn't working.
It's good the lower dose did work because mabs are so expensive anyway. If Medicaid ever stops paying for the most expensive treatments like 100,000$ provenge (which extends like by 4 months average) DNDN will be 10 cents a share. $2.14 now.
could be bad management, but for whatever reason the company is unknown, or known mostly as "the company that had the big trial delay and now Pfizer may be bailing on them". They have had a long period of nothing going on.
Hopefully that is changing, may take a little time for people to think so. Get it together Scott.
Who says they don't like it? The stock went up once the smart people realized it wasn't bad news.
I think the smart wallstreet people wanted to see if dummies would "sell on the news" as the old axiom goes, and like John said there is a lot to repair here before people really trust management.
Lets hope the rest of this year and next Scott pulls it together.
I know they saif they were going to use the higher dose in the cohort two, but the results from these patients seem pretty good in the low dose group. That's a good sign, three times the dose means three times the price. If the low dose plus sutent works better.... that's good too.
The next 9 patients were initiated at a dose of 24 mg/kg. Of these higher-dose patients: 4 had progressive disease at or before the end of four months; 2 were progression-free at the four-month mark (with 1 of these 2 deemed a partial responder per RECIST criteria); and the remaining 3 have not yet reached their four-month mark.
"A bimodal distribution of patients has emerged, whereby half the patients experience disease progression early, consistent with their "last line" prognosis, while the other half experience stable disease, with a number of them still progression-free beyond one year," said Dario Paggiarino, M.D., chief development officer of Lpath. "Based on the safety profile and the promising results, we have moved beyond the first cohort of 22 evaluable patients into a second cohort, allowing us to enroll up to a total of 54 evaluable patients."
"I have been impressed with the preliminary signs of activity that I am observing with ASONEP," commented Sumanta Pal, M.D., from the City of Hope in Los Angeles, one of the lead investigators in the study. He continued, "The bimodal distribution is promising and supports an extension of the study. Furthermore, ASONEP appears to be well tolerated by the patients, which is not often the case with experimental cancer drugs."
SAN DIEGO, July 24, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, reported interim results in a Phase 2a single-arm, open-label trial where ASONEP™ is being investigated as a treatment for metastatic renal cell carcinoma (RCC) in patients that have failed at least one therapy involving a VEGF inhibitor (e.g., Sutent®/ sunitinib maleate) and no more than one mTOR inhibitor (e.g., Afinitor®/everolimus), with a maximum of three failed treatments in all. This patient population is considered "last line," and the literature suggests cancer progression in this population within a one-to-two month time frame.
Lpath has enrolled 26 patients in the study. ASONEP has a favorable safety profile thus far, with no serious adverse events (SAEs) deemed to be drug-related.
The first 17 patients were initiated at a dose of 15 mg/kg. Of these "lower-dose" patients: 7 had progressive disease at or before the end of four months; 8 were progression-free at the four-month mark (with 1 of these patients deemed a partial responder per Response Evaluation Criteria in Solid Tumors (RECIST) criteria and with 3 of these patients experiencing reduced tumor volume, but not enough to be categorized as a RECIST-based partial responder); and 2 exited the study due to SAEs unrelated to the drug prior to the four-month mark (and are not considered evaluable). Notably, of the 8 patients that were stable or better as of month four, 2 are now in their fifteenth month on the study, 1 is in month thirteen, and 1 is in month ten. An additional patient was stable through month seven, but then missed six treatments during a vacation, and shortly thereafter progressed.